Hospital Formulary Status Yes (parenteral inj)
In-Hospital Cost will be updated
PharmaCare Formulary Status No
Special Authority None
PharmaCare Coverage None
Outpatient Cost 50mg powder for soln - $130.68-143.75/vial
Fungicidal therapy of yeast/fungus/mold infection (not for use in urinary tract infection).
Invasive candidiasis, aspergillosis, cryptococcosis.
Visceral/mucocutaneous Leishmaniasis.
Induction therapy for dimorphic fungii (cocci, blasto, histo).
Frequency depends on course, but daily reasonable during initiation
Careful attention to electrolyte and fluid status with boluses (usually 500ml) of NS before and after infusion
Same toxicities as conventional Amphotericin B but with less frequency
Nephrotoxicity (IV)
Infusion-related reactions (IV)
Phlebitis (IV)
Electrolyte abnormalities (IV)
Anemia (IV)
Main concern is concomitant nephrotoxins - use should be minimized during amphotericin therapy
Digoxin - increased digoxin toxicity with hypokalemia
Antimicrobial class: Antifungal, Polyene - Lipid Formulation (designed to minimize toxicity)
Lipid associated AmB is taken up preferentially by phagocytic cells and concentrated at sites of infection while minimizing renal exposure.
Average serum half life: 150.0 hr
Urine penetration: Poor
Lung penetration: Therapeutic
Biliary penetration: Therapeutic